New Horizons in MASH Management

CME/CNE/CPE

Walter E. Washington Convention Center
Sunday, November 9, 2025 | 12:30 PM - 2:00 PM TZ
event presence logo
Supported by an independent educational grant from Inventiva.

overview

As obesity and metabolic diseases fuel a global surge in metabolic dysfunction-associated liver disease (MASLD) and metabolic-associated steatohepatitis (MASH) cases, many physicians remain unfamiliar with the burden of disease and its underlying pathophysiology. In this symposium, expert faculty will illuminate the key pathophysiologic drivers behind MASLD/MASH, such as dysregulated lipid metabolism, impaired insulin sensitivity, oxidative stress, and inflammatory fibrotic processes. Faculty will review key clinical data of emerging therapies poised to alter the treatment landscape for MASH, including incretins, peroxisome proliferator–activated receptor (PPAR) agonists, fibroblast growth factor 21 (FGF-21) analogues, and thyroid hormone receptor-β (THR-β) agonists, and how these novel agents may be incorporated into comprehensive MASH treatment strategies.

Presented for attendees of The Liver Meeting® 2025. This event/function is provided by Medscape Education and supported by Industry Supporter(s). This is not an official event/function of the American Association for the Study of Liver Diseases.

Enhance Your Experience With MedChallenge!

This event features MedChallenge, a new feature from Medscape that allows you to go head-to-head against your peers in a series of medical questions. Earn points, deepen your knowledge, and fight for the top spot on the leaderboard!

faculty

Chair

​​Rohit Loomba, MD, MHSc

Professor of Medicine

Chief, Division of Gastroenterology and Hepatology

Director, UCSD MASLD Research Center

UC San Diego Health

San Diego, California, United States​

Panelist

Philip Newsome, MBChB, PhD, FRCPE, FMedSci

Director of Roger Williams Institute of Liver Studies

Professor of Hepatology

King's College London & Hon Consultant Hepatologist King's College Hospital

Director of King's Health Partners Centre for Translational Medicine

King’s College

London, England

​

Panelist

​​Manal Abdelmalek, MD, MPH, FAASLD

Professor of Medicine

Director, MASLD Clinical Research Program

Mayo Clinic

Rochester, Minnesota, United States

AGENDA

12:30 PM TZ

Welcome and Introductions

12:35 PM TZ

Pathophysiology of MASLD and MASH

Rohit Loomba, MD, MHSc

12:50 PM TZ

Emerging Therapies for MASH

All Faculty

1:45 PM TZ

Concluding Remarks and Q&A

Rohit Loomba, MD, MHSc

2:00 PM TZ

Adjourn

backstage pass
Enhance Your Virtual Experience With Backstage Pass! Backstage Pass provides an intimate virtual session where you can interact with faculty, address case-based questions, and facilitate relationship building.
*Video encouraged*

LOCATION

Walter E. Washington Convention Center

801 Allen Y. Lew Place NW, Washington, DC, 20001

Room : 150

TARGET AUDIENCE

This educational activity is intended for an audience of gastroenterologists/hepatologists, endocrinologists/diabetologists, primary care physicians, nurse practitioners/physician assistants, nurses, and pharmacists in the United States.

GOAL STATEMENT

The goal of this activity is for learners to be better able to understand the relationship of metabolic dysfunction-associated steatohepatitis (MASH) pathology and the mechanism of emerging treatments, including data on efficacy and safety for these novel treatment approaches.

LEARNING OBJECTIVES

[bold]Upon completion of this activity, participants will:[/bold] [para]Have increased knowledge regarding the[/para] [list][item]Data for new and emerging treatments for MASH [item]Mechanisms of action for emerging MASH therapies in relation to MASH pathophysiology [item]Similarities and differences of endpoints for clinical trials for emerging MASH therapies [/list]

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
accreditation logo
medscape logo
[title]For Physicians[/title] [text]Medscape, LLC designates this live activity for a maximum of 1.5 [bold][italic]AMA PRA Category 1 Credit(s)[/italic][super]TM[/super][/bold]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.[/text] [break] [title]For Nurses[/title] [text]Awarded up to 1.5 contact hour(s) of nursing continuing professional development for RNs and APNs.[/text] [break] [title]For Pharmacists[/title] [text]Medscape designates this continuing education activity for ​1.50​ contact hour(s) (​0.150​ CEUs) (Universal Activity Number: ​JA0007105-0000-25-224-L01-P​).[/text]
© 2025 MedscapeLIVE! All Rights Reserved | Medscape Education Terms of Service | Privacy Policy